LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

Search

Akebia Therapeutics Inc

Затворен

СекторЗдравеопазване

3.64 -2.67

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

3.59

Максимум

3.74

Ключови измерители

By Trading Economics

Приходи

29M

6.1M

Продажби

11M

57M

EPS

0.025

Марж на печалбата

10.66

Служители

181

EBITDA

20M

14M

Препоръки

By TipRanks

Препоръки

Силна покупка

12-месечна прогноза

+90.22% upside

Дивиденти

By Dow Jones

Следващи печалби

7.08.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

345M

956M

Предишно отваряне

6.31

Предишно затваряне

3.64

Техническа оценка

By Trading Central

Увереност

Strong Bullish Evidence

Akebia Therapeutics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

27.06.2025 г., 20:51 ч. UTC

Печалби

These Stocks Moved the Most Today: Nike, Nvidia, Coinbase, Palantir, Boeing, Newmont, Core Scientific, and More -- Barrons.com

27.06.2025 г., 20:50 ч. UTC

Пазарно говорене

Tech, Media & Telecom Roundup: Market Talk

27.06.2025 г., 20:50 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

27.06.2025 г., 20:48 ч. UTC

Пазарно говорене

Computer Lobby Cheers Move to Punish Canada Over Digital Tax -- Market Talk

27.06.2025 г., 20:46 ч. UTC

Пазарно говорене

Market Talk Roundup: Latest on U.S. Politics

27.06.2025 г., 20:46 ч. UTC

Пазарно говорене

Canada Dismissal of Risk From Digital Tax Is 'Shocking' -- Market Talk

27.06.2025 г., 19:31 ч. UTC

Пазарно говорене

Canada CEOs Call for Carney to Drop Digital Tax -- Market Talk

27.06.2025 г., 19:19 ч. UTC

Пазарно говорене

Oil Posts Weekly Loss As Geopolitical Premium Evaporates -- Market Talk

27.06.2025 г., 19:16 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures Snap Losing Streak -- Market Talk

27.06.2025 г., 18:57 ч. UTC

Придобивния, сливания и поглъщания

Russian Oligarch Roman Abramovich Is Evraz PLC's Largest Shareholder With 29% Stake -- WSJ

27.06.2025 г., 18:57 ч. UTC

Придобивния, сливания и поглъщания

Evraz North America Parent Evraz PLC Remains Under Sanction by U.K. -- WSJ

27.06.2025 г., 18:57 ч. UTC

Придобивния, сливания и поглъщания

Evraz North America Employs About 3,400 People, Has 3.5 Million Tons of Finished Steel Capacity -- WSJ

27.06.2025 г., 18:57 ч. UTC

Придобивния, сливания и поглъщания

Atlas Holdings to Buy Evraz North America for Up to $500 Million, Companies Say -- WSJ

27.06.2025 г., 18:57 ч. UTC

Придобивния, сливания и поглъщания

Atlas Holdings to Buy Evraz North America for Up to $500 Million, Companies Say -- WSJ

27.06.2025 г., 18:42 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

27.06.2025 г., 18:42 ч. UTC

Пазарно говорене

Canada's Carney 'Likely Amenable' to Dropping Digital-Services Tax -- Market Talk

27.06.2025 г., 18:39 ч. UTC

Пазарно говорене
Печалби

Nike's Second-Half Prospects Can Get Better as Worst is Behind it -- Market Talk

27.06.2025 г., 18:29 ч. UTC

Пазарно говорене

Canada Recession Risks Likely to Rise With Trump's Termination of Tariff Talks -- Market Talk

27.06.2025 г., 18:18 ч. UTC

Пазарно говорене

Canadian Dollar Sharply Weakens on Trump's Surprise End to US-Canada Tariff Talks -- Market Talk

27.06.2025 г., 18:16 ч. UTC

Пазарно говорене

Trump's Threat Against Canada Weighs Down Treasurys -- Market Talk

27.06.2025 г., 17:16 ч. UTC

Пазарно говорене

U.S. Oil Rig Count Falls by 6 to 432 -- Market Talk

27.06.2025 г., 17:08 ч. UTC

Печалби

McDonald's Stock Has Slipped. One Analyst Sees 21% Upside. -- Barrons.com

27.06.2025 г., 16:52 ч. UTC

Придобивния, сливания и поглъщания

Nike Stock Soars After Earnings. Is It Time to Just Buy It? -- Barrons.com

27.06.2025 г., 16:22 ч. UTC

Печалби

These Stocks Are Moving the Most Today: Nike, Nvidia, Coinbase, Palantir, Boeing, Newmont, Core Scientific, and More -- Barrons.com

27.06.2025 г., 16:20 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

27.06.2025 г., 16:20 ч. UTC

Пазарно говорене

Tech, Media & Telecom Roundup: Market Talk

27.06.2025 г., 16:20 ч. UTC

Пазарно говорене

Auto & Transport Roundup: Market Talk

27.06.2025 г., 16:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

27.06.2025 г., 15:59 ч. UTC

Пазарно говорене

Gold Futures Slump on Improving Risk Appetite -- Market Talk

27.06.2025 г., 15:56 ч. UTC

Пазарно говорене

Nvidia Again Helping To Power New S&P Highs -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Akebia Therapeutics Inc Прогноза

Ценова цел

By TipRanks

90.22% нагоре

12-месечна прогноза

Среден 7 USD  90.22%

Висок 8 USD

Нисък 6 USD

Според 3 анализатори от Wall Street, предложили 12-месечна ценова цел за Akebia Therapeutics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

3 ratings

3

Купи

0

Задържане

0

Продай

Техническа оценка

By Trading Central

2.345 / N/AПодкрепа & съпротива

Краткосрочен план

Strong Bullish Evidence

Средносрочен план

Strong Bullish Evidence

Дългосрочен план

Bullish Evidence

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Akebia Therapeutics Inc

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.